Showing 621 - 640 results of 18,329 for search '(( 50 ((we decrease) OR (nn decrease)) ) OR ( 59 ((mean decrease) OR (a decrease)) ))', query time: 0.79s Refine Results
  1. 621

    Longitudinal Lung Function Decrease in Subjects with Spontaneous Healed Pulmonary Tuberculosis by Seung Heon Lee (713097)

    Published 2016
    “…<div><p>Objective</p><p>We compared the longitudinal course of post-bronchodilator Forced Expiratory Volume in 1 second (pFEV1) over a 10-year period in subjects with spontaneous healed pulmonary tuberculosis (SHPTB) with that in normal subjects.…”
  2. 622
  3. 623

    Design, expression and functional characterization of a thermostable xylanase from <i>Trichoderma reesei</i> by Jun He (46556)

    Published 2019
    “…<i>reesei</i> xylanase (Xyn2), and novel flexible regions of the enzyme were identified based on B-factor, a molecular dynamics (MD) parameter. To improve thermostability of the Xyn2, disulfide bonds were introduced into the unstable flexible region by using site-directed mutagenesis and two recombinant xylanases, XM1 (Xyn2<sup>Cys12-52</sup>) and XM2 (Xyn2<sup>Cys59-149</sup>) were successfully expressed in <i>Pichia pastoris</i>. …”
  4. 624

    Does Mean Platelet Volume Decrease in the presence of Coronary Artery Fistula? by Isa Sincer (7234577)

    Published 2019
    “…Methods: 70 patients with normal coronary arteries and 50 with coronary artery fistulas were included. …”
  5. 625
  6. 626
  7. 627
  8. 628
  9. 629
  10. 630
  11. 631
  12. 632
  13. 633
  14. 634
  15. 635
  16. 636
  17. 637

    TUT1 suppression yields broad decreases in miRNA expression. by Emily C. Knouf (434880)

    Published 2013
    “…(<b>A</b>) We compared the abundance of miRNAs detectable with at least 50 counts on the NanoString platform in the enzyme suppressed vs. negative control siRNA-transfected cells. …”
  18. 638
  19. 639
  20. 640

    S1 Dataset - by Nelmo Jordão Manjate (16324619)

    Published 2023
    “…For diagnosis by nasal Ag-RDTs, Panbio was MZN 547.00 (USD 8.90), COVIOS was MZN 768.00 (USD 12.50), and LumiraDx was MZN 798.00 (USD 13.00). Medical supplies expenditures represented the main driver of the final cost (>50%), followed by personnel and overhead costs (mean 15% for each). …”